Compositions and methods for inhibiting the proliferation of enterotoxigenic Bacteroides fragilis
Inventors
Yoon, Seong Jun • Son, Jee Soo • KIM, In Hwang • Paik, Hyoung Rok • OH, Eun Kyoung • JUN, Soo Youn • Kang, Sang Hyeon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12263196-B2
Publication Date
2025-04-01
Expiration Date
Abstract
A composition for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes a Siphoviridae bacteriophage (Bac-FRP-3) having an ability to lyse the enterotoxigenic Bacteroides fragilis cells and a pharmaceutically acceptable carrier. A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis includes administering to a subject a Siphoviridae bacteriophage and lysing the enterotoxigenic Bacteroides fragilis cells by the Siphoviridae bacteriophage.
Core Innovation
The invention relates to a method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis by administering a composition containing a Siphoviridae bacteriophage Bac-FRP-3. Bac-FRP-3 is deposited in the Korean Collection for Type Culture under accession number KCTC 14401BP and is characterized by an ability to lyse enterotoxigenic Bacteroides fragilis cells. The composition further specifies the genome sequence as set forth in SEQ ID NO: 1.
Bac-FRP-3 is described as having a latent period of 10–100 minutes and a burst size of 1000–2100 plaque-forming units per infected cell. Bac-FRP-3 is also characterized by structural proteins in sizes of approximately 25 kDa, 48 kDa, 68 kDa, 75 kDa, 117 kDa, and 245 kDa.
The invention also addresses the clinical target scope and formulation content of the Bac-FRP-3 composition. The disease target includes acute and chronic intestinal infections or disease, including bacteremia, diarrhea, colitis, colonic neoplasia, and colorectal or colon cancer. The described composition includes pharmaceutically acceptable carriers and a specified concentration of Bac-FRP-3 in the range of 1×10^4 PFU/ml to 1×10^15 PFU/ml or 1×10^4 PFU/g to 1×10^15 PFU/g.
Claims Coverage
The document contains one independent claim. It specifies a method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis, with defined phage identity, phage functional kinetics, phage structural protein sizes, and a specified Bac-FRP-3 concentration range.
Enterotoxigenic Bacteroides fragilis prevention or treatment with Bac-FRP-3 composition
A method for preventing or treating an infection or disease caused by enterotoxigenic Bacteroides fragilis by administering to a subject a composition containing Siphoviridae bacteriophage Bac-FRP-3 and a pharmaceutically acceptable carrier, wherein Bac-FRP-3 has an ability to lyse enterotoxigenic Bacteroides fragilis cells.
Deposited Bac-FRP-3 with genome sequence set forth in SEQ ID NO:1
Bac-FRP-3 is deposited in the Korean Collection for Type Culture under accession number KCTC 14401BP and has the genome sequence as set forth in SEQ ID NO: 1.
Defined infectivity kinetics and burst size
Bac-FRP-3 has a latent period of 10–100 minutes and a burst size of 1000–2100 PFU per infected cell.
Defined structural protein sizes
Bac-FRP-3 has structural proteins in the size of approximately 25 kDa, 48 kDa, 68 kDa, 75 kDa, 117 kDa, and 245 kDa.
Specified Bac-FRP-3 concentration in composition
The composition has a concentration of Bac-FRP-3 of 1×10^4 PFU/ml to 1×10^15 PFU/ml or 1×10^4 PFU/g to 1×10^15 PFU/g.
Carriers and excipients for the administered composition
The composition includes a pharmaceutically acceptable carrier selected from specified materials, and optionally includes one or more optional ingredients selected from lubricant, wetting agent, sweetener, flavor, emulsifier, suspending agent, and preservative.
Acute or chronic intestinal disease scope
The method is applied to an acute or chronic intestinal infection or disease selected from diarrhea, colitis, colonic neoplasia, bacteremia, or colorectal cancer.
Specified physical dosage forms
The composition is provided in one of specified physical forms selected from solution, suspension, emulsion in oil, water-soluble medium, extract, powder, granule, tablet, or capsule.
Overall, the claim coverage is grounded in a Bac-FRP-3-based prevention or treatment method for enterotoxigenic Bacteroides fragilis infections, defined by KCTC deposition and SEQ ID NO: 1 genome sequence, latent period and burst size, structural protein sizes, and a specified phage concentration range. Dependent claims further define carriers, excipients, disease scope, and physical dosage forms.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?